The Gap shares lower after reporting earnings after the bell.
The Gap shares lower after reporting earnings after the bell.
The "European Defense Integration - Thematic Research" report has been added to ResearchAndMarkets.com's offering.
England win by six wickets
The world's biggest diesel engine factory in Tremery, eastern France, is undergoing a radical overhaul - it's switching to make electric motors. From less than 10% of output in 2020, electric motor production at Tremery will double to around 180,000 in 2021, and is planned to reach 900,000 a year - or more than half the plant's peak pre-pandemic output - by 2025. The shift is testament to a car industry in flux.
A third class action lawsuit has been filed in Europe against Apple seeking compensation -- for what Italy's Altroconsumo consumer protection agency dubs "planned obsolescence" of a number of iPhone 6 models. The action relates to performance throttling Apple applied several years ago to affected iPhones when the health of the device's battery had deteriorated -- doing so without clearly informing users. The class action suit in Italy is seeking €60M in compensation -- based on at least €60 in average compensation per iPhone owner.
Andrea Pitter Shares Journey to Creating a Bridal Empire & Why Representation Matters While Gracing The Cover of The Knot Magazine 2021 Spring Issue
You may have started gig working to raise some extra cash, to explore self-employment part-time, or to improve your work-life balance. As a gig worker, you are likely eligible to open and use a solo 401(k), which is one of the more powerful tax-advantaged retirement accounts available. The solo 401(k) functions much like a standard 401(k) in terms of tax advantages and contribution limits.
Michael Owen has described Chelsea's sacking of Frank Lampard as an "absolutely staggering decision" and questioned the "politics" at the club. Lampard, the Blues' record goalscorer, was sacked on Monday morning after a run of five defeats from eight Premier League games. Former Derby boss Lampard signed a three-year deal in the summer of 2019 and, in spite of a transfer ban, led Chelsea to the FA Cup final and a fourth-place finish in his first managerial campaign at Stamford Bridge.
These two REITs have a history of raising dividends and managing their operations well in good times and bad.
(Bloomberg) -- Oil traded near $52 a barrel in New York, erasing earlier gains, even as supply curtailments grew.Iraq pledged to cut output in January and February to compensate for pumping more than its OPEC+ quota last year, and Libyan guards halted some crude exports after a pay dispute. Russian seaborne exports of its flagship Urals grade will fall by about 20% in February, while oil stored at sea has dropped to the lowest level since April.Futures, however, turned lower as equity markets wiped out gains. Merck & Co. said it was discontinuing development of its two experimental Covid-19 vaccines, at a time of heightened anxiety over the supply of coronavirus inoculations.Oil’s rally has stalled over the past week as a resurgence of the virus in China spurred localized lockdowns, while restrictions remained in place in many European countries. While that could hit demand, supply is also being reduced. Iraq will pump 3.6 million barrels a day in January and February, the lowest level since early 2015. Saudi Arabia is also planning sharp curbs over the next two months.“The implementation of the compensatory cuts is likely to boost confidence in the agreement signed by OPEC and its allies,” said Eugen Weinberg, an analyst at Commerzbank AG. “The supply deficit could therefore turn out to be somewhat bigger in the first quarter.”The supply curtailments are strengthening the market’s structure. Early Monday, Brent’s prompt timespread was 20 cents a barrel in backwardation -- a bullish market formation where near-dated contracts are more expensive than later dated ones. That’s the widest spread since March.See also: Negative-Rate Supertankers About to Get Junked on Asia’s BeachesThe world economy is facing a tougher start to 2021 than expected as Covid-19 infections surge and as it takes time to roll out vaccinations. Global growth is still on course to rebound quickly from the recession of last year, but it may take longer to ignite and not be as healthy as previously forecast. The World Bank trimmed its prediction to 4% in 2021 and the International Monetary Fund will this week update its own outlook.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
during the forecast period. The market is driven by the growth of the microelectronics industry, characterized by the emergence of new technologies. The silicon wafers segment is projected to register the highest CAGR during the forecast period.New York, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Electronic Chemicals and Materials Market by Type, Application and Region - Global forecast to 2025" - https://www.reportlinker.com/p05827139/?utm_source=GNW Silicon wafers are a thin slice of semiconductor made out of crystalline silicon and a key component in the fabrication of integrated circuits and serve as a substrate for microelectronics devices. The primary use of silicon wafer is in integrated circuits, which are the basic building block of any electronic devices, such as computers and smartphones.Semiconductor application segment is expected to hold the larger market share during the forecast period.A semiconductor is a solid chemical compound or element, which can conduct electricity under certain conditions depending upon the dopants added during the manufacturing process.Integrated circuits and printed circuit boards are the basic building blocks of any semiconductor material.These semiconductor devices require proper maintenance for their functionality; hence, certain electronic chemicals and materials are used to clean, etching, polishing, doping, and servicing semiconductors.APAC is estimated to be the fastest-growing electronic chemicals and materials market during the forecast period.APAC is estimated to be the fastest-growing electronic chemicals and materials market during the forecast period due to the rapid growth of the global electronics industry, which has driven the demand for printed circuit boards in the region. The printed circuit board industry’s growth is directly associated with the development in telecommunications and IT, smart cards, electronic gaming, and consumer goods applications.Extensive primary interviews were conducted to determine and verify the market size for several segments and sub-segments and the information gathered through secondary research.The breakup of primary interviews is given below:• By Company Type - Tier 1 – 55%, Tier 2 – 30%, and Tier 3 – 15%• By Designation - C level – 42%, Director Level – 30%, and Others – 28%• By Region - APAC– 40%, Europe – 28%, North America – 25%, Rest of World – 7%The leading players in the electronic chemicals and materials market are Linde plc (Ireland), Air Products (US), Cabot Microelectronics (US), BASF AG (Germany), Hitachi Chemical (Japan), Air Liquide (France), Solvay A.G. (Belgium), Shin-Etsu (Japan), Covestro (France), and Songwon (South Korea).Research Coverage:This research report categorizes the electronic chemicals and materials market based on type, application, and region.The report includes detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the market’s growth.A detailed analysis of the key industry players has been done to provide insights into business overviews and recent developments associated with the market.Key Benefits of Buying the ReportThe report will help market leaders/new entrants in this market in the following ways:1. This report segments the electronic chemicals and materials market comprehensively and provides the closest approximations of market sizes for the overall market and sub-segments across verticals and regions.2. The report will help stakeholders understand the market’s pulse and provide them information on the key market drivers, restraints, challenges, and opportunities.3. This report will help stakeholders understand the major competitors and gain insights to enhance their position in the business. The competitive landscape section includes developments such as new product launches.4. The report includes COVID-19 impact on the electronic chemicals and materials market.Read the full report: https://www.reportlinker.com/p05827139/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
New Fellowship Program Addresses Need for Enhanced Resources, Funding & Mentorship to Help Underrepresented Businesses in the Wedding Industry Thrive
IRVING, Texas, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or “Company”) (NASDAQ: XELA), a location-agnostic global business process automation (BPA) leader, announced that its Board of Directors has approved a 1-for-3 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, January 25, 2021. Exela’s Board of Directors approved the split and determined the 1-for-3 ratio to be appropriate to meet Exela’s goals of improving the marketability and liquidity of its common stock, compliance with Nasdaq listing requirements and continued focus by the Company’s management team on the initiatives underway to strengthen its balance sheet and improve shareholder value. As a result of the reverse split, each three shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The Company’s shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing upon market open on January 26, 2021. Immediately after the reverse split becomes effective, there will be approximately 49.2 million shares of common stock issued and outstanding. About Exela Technologies Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of expertise operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune® 100. With foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry department solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and public sectors. Through cloud-enabled platforms, built on a configurable stack of automation modules, and over 21,000 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.Forward-Looking Statements Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "may", "should", "would", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "will", "expect", "outlook" or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, estimated or anticipated future results and benefits, future opportunities for Exela, and other statements that are not historical facts. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties, including without limitation those discussed under the heading "Risk Factors" in Exela's Annual Report and other securities filings. In addition, forward-looking statements provide Exela's expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela's assessments to change. These forward-looking statements should not be relied upon as representing Exela's assessments as of any date subsequent to the date of this press release. Investor and/or Media Contacts:Vincent KondaveetiE: email@example.comT: 929-620-1849 Mary Beth BenjaminE: IR@exelatech.com T: 646-277-1216
Trixie Underground Exposure Figure 1: Active mine face on the T2 structure, with the bonanza grade xocomecatlite-bearing footwall breccia and significant high-grade quartz stockwork veining developed in the immediate hanging wall of breccia. The T2 structure dips steeply to the east, away from the lower levels of historic mine development. Table of Au Ag Composites Table 1: Channel face sampling of the T2 structure with composite gold (Au) and silver (Ag) grades listed by their continuous width in oz/t. Locations of channel samples are referenced north and south of the 609 cross-cut, and are graphically shown in Figure 2 below. Bonanza and high-grade mineralization is currently developed over 302 feet of strike length and remains open in all directions. T-2 structure Au Ag composites Figure 2: Plan map of the T2 structure, striking north-south with significant bonanza and high-grade gold and silver mineralization recorded over a strike length of 302 feet to date. Channel face sampling with composite gold (Au) and silver (Ag) grades in oz/t are listed, with mineralization remaining open in all directions. The T2 structure was intercepted only 44 ft east of the historic Trixie mine development on the 625’ level. EAST TINTIC DISTRICT, Utah, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Tintic Consolidated Metals LLC (“TCM” or the “Company”) is pleased to announce the discovery of ultra-high-grade gold and silver bearing veins within its wholly owned Trixie mine in the East Tintic District, Utah. Highlights: The Company recommissioned its Trixie Au-Ag mine in late 2020 and rapidly began exploration development on the existing 625’ level. Shortly after drifting began on this level, a previously unidentified ultra-high-grade vein was intercepted, which has been denoted the “T2 structure”. Horizontal development along this newly discovered, steeply dipping mineralized structure has demonstrated it to be continuously mineralized for at least 302 feet, with an average width of 6.6 feet and carrying a weighted average grade of 15.5 ounces per ton (oz/t) of gold (uncut) and 21.5 oz/t of silver. The T2 structure is characterized by the presence of abundant bright green xocomecatlite (a rare copper tellurate mineral) within a 2-foot-wide footwall breccia, with adjoining intense quartz stockwork veining developed in the hanging wall of the structure over widths of 3 to 12 feet. Channel face sampling of these intercepts has revealed gold grades ranging up to 102 oz/t of gold and 192 oz/t of silver over continuous widths of up to 8 feet (see Table 1 for details). Tom Bowens, President and CEO of the Company said, “Since TCM was formed as a joint venture between IG Tintic (75%) and Chief Consolidated (25%) in June 2019 there has been remarkable progress made. In only 20 months, the Company has reclaimed the surface infrastructure, reopened the first of a series of historic precious metal mines, and made a significant new gold discovery. The pace at which the Company has added value to the district is a testament to the skills of the Company’s team of exploration, mining, and development professionals. It is the Company’s vision to bring this famous district back on-line as a major US gold, silver and copper production center over the coming years. This discovery is a very significant step towards achieving that goal and provides a remarkable platform for the future development of the Company.” Details and Background: The Trixie mine is the first of a series of legacy mines TCM is targeting to re-open on its extensive property holdings. Importantly, the Trixie mine is fully permitted with necessary environmental permits and bonding in place. The adjacent Eureka Standard high-grade gold mine anticipated is currently being investigated for a potential re-opening in 2023. Furthermore, TCM is planning exploration for a prospective deep copper-gold porphyry deposit, with multiple porphyry targets identified on the property. The T2 structure strikes north-south, dips steeply to the east, and has been developed thus far over a strike length of 302 feet. Significant high-grade gold and silver mineralization has been recorded over the entire strike length and over widths ranging from 3 to 12 feet, with mineralization remaining open in all directions. Average gold grades within the xocomecatlite-bearing footwall breccia of the T2 structure typically range from 10 to over 100 oz/t, with the adjacent hanging wall stockwork vein zones averaging 1 to 3 oz/t of gold. Abundant visible gold is present in some ultra-high-grade samples. Importantly, this newly identified ultra-high-grade structure dips steeply towards the east, away from the historic mine development at depth. Significant depth potential and additional high-grade mineralization on this structure is interpreted both up and down dip. The identification and eventual exploitation of extensions to the newly discovered mineralization will be greatly enhanced by the existing infrastructure. In addition to the currently operational 625’ level, refurbishment is presently underway on the 750’ level. Future work will refurbish existing infrastructure down to the 1350’ level. Channel face samples from the T2 structure with composite gold and silver grades are listed in Table 1. A typical underground mining face developed on the bonanza-grade footwall breccia and the adjacent hanging wall stockwork zone is displayed in Figure 1, and the locations of channel face samples are graphically displayed on the plan map in Figure 2. Figure 1: https://www.globenewswire.com/NewsRoom/AttachmentNg/ab9f4b05-b06e-4a09-b053-233b9ec6c626Active mine face on the T2 structure, with the bonanza grade xocomecatlite-bearing footwall breccia and significant high-grade quartz stockwork veining developed in the immediate hanging wall of breccia. The T2 structure dips steeply to the east, away from the lower levels of historic mine development. Table 1: https://www.globenewswire.com/NewsRoom/AttachmentNg/c9852c8a-aba3-4207-b999-a3a0b29fd318Channel face sampling of the T2 structure with composite gold (Au) and silver (Ag) grades listed by their continuous width in oz/t. Locations of channel samples are referenced north and south of the 609 cross-cut, and are graphically shown in Figure 2 below. Bonanza and high-grade mineralization is currently developed over 302 feet of strike length and remains open in all directions. The Company intends to continue a combination of lateral and raise development, along with short drillhole resource definition drilling along the T2 structure, to obtain better definition of the resource and reserves contained within this high-grade structure. Access also has been gained to the historic next-lower 750’ underground level of the Trixie mine, and lateral development on this level to the T2 structure will commence shortly. The reserves from the T2 structure will then be added to those resources defined prior to its discovery to calculate an overall resource and reserve estimate for the Trixie mine. The Company intends to complete this updated resource and reserve calculation in 2021. Figure 2: https://www.globenewswire.com/NewsRoom/AttachmentNg/ce034691-2ebe-494f-8fa3-d75b979458f3Plan map of the T2 structure, striking north-south with significant bonanza and high-grade gold and silver mineralization recorded over a strike length of 302 feet to date. Channel face sampling with composite gold (Au) and silver (Ag) grades in oz/t are listed, with mineralization remaining open in all directions. The T2 structure was intercepted only 44 ft east of the historic Trixie mine development on the 625’ level. In addition to the Trixie mine, the Company is in the process of developing an exploration program for the Eureka Standard mine, located approximately 2,000 feet north of the Trixie main shaft. The Eureka Standard mine was operated until 1947 and was historically the highest-grade precious metal mine in the East Tintic District. The Eureka Standard workings are connected to the Trixie main shaft by an underground drift at the 1350’ level. Historic production at the Eureka Standard mine was halted at the then groundwater table of the 1450’ sublevel, on a high-grade ore shoot averaging 1 to 1.8 oz/t of gold, with mineralization remaining completely open at depth. The Company is targeting the Eureka Standard mine for re-opening within 2 years, initially focusing on the depth extensions of the high-grade T2 mineralized structure. The Company is also developing a program to explore for a prospective deep porphyry copper-gold system underlying the East Tintic District, similar to the Bingham Canyon deposit located approximately 50 miles north of the project. The Company has engaged Richard Leveille, the former President of Freeport McMoran Exploration Corporation, to lead this porphyry exploration effort. About Tintic Consolidated Metals LLC TCM is a private US based mining company whose assets are located in the historic Tintic Mining District of Utah. TCM is a Joint Venture between IG Tintic LLC (“IGT”), the 75% owner and manager, and Chief Consolidated Mining Company (“Chief”), which owns 25%. Over the past 100 years, Chief consolidated numerous small mining claims into a single large land package. TCM holds nearly 14,000 acres of patented mineral rights within this package, including 7,000 acres of surface rights and numerous legacy assets, among them 6 existing mines with over 20 miles of underground workings, thousands of pages of historic data and multiple facilities. Two of these existing mines are fully permitted and have approved reclamation plans and accompanying cash bonds. The table below summarizes the Tintic District’s historic production, which would amount to over $16 billion at current metal prices. TCM has set an aggressive goal of re-opening one of the remaining legacy mines every two years. The Eureka Standard mine is the next legacy mining operation targeted for re-development. In addition, TCM is investigating the potential for a deep copper porphyry deposit in the district. Qualified Persons and Sampling Protocol Thomas E Bowens, CPG, President & CEO of Tintic Consolidated Metals, a Qualified Person within the meaning of US SEC Compliance Guidelines, has reviewed, verified, and approved the scientific and technical disclosure contained in this news release. However, this news release is not represented by the Company to be compliant with SEC S-K 1300 or similar national standards required of public companies. This media release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, “would” or “should” occur or be achieved. Forward-looking statements are necessarily based on several opinions, estimates and assumptions that TCM’s management considered appropriate and reasonable as of the date such statements are made, and are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact included herein are forward-looking statements. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities. For more information, visit www.tinticmetals.com and igglobalgroup.com. Contact: firstname.lastname@example.org
(Bloomberg) -- Merck & Co. is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines.The U.S. drug giant, which has a history of successfully developing vaccines, had adopted a different strategy from rivals Pfizer Inc., Moderna Inc. and Johnson & Johnson, using a more traditional approach of focusing on shots based on weakened viruses. One, called V590, borrowed technology from Merck’s Ebola inoculation, while the other, V591, is based on a measles vaccine used in Europe.Both were laggards in the vaccine-development race. Merck finished recruiting the first participants for early-stage safety studies near the end of 2020, when front-runners Pfizer and Moderna were preparing to report late-stage data on their shots’ effectiveness. Merck received interim results from its trials this month.The results were “disappointing, and a bit of a surprise,” said Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories. Both shots generated fewer neutralizing antibodies to halt infection than other Covid-19 vaccines, and produced inferior immune responses compared with people who had naturally contracted the coronavirus.“We didn’t have what we needed to be able to move forward,” Kartsonis said in an interview Sunday. After evaluating the data, Merck’s senior leadership decided to discontinue the programs and divert resources to the company’s efforts to develop Covid-19 treatments.Merck fell 1.4% Monday before markets opened in New York. The shares have lost 9.7% over the past 12 months through Friday’s close.Vaccine AnxietyWhile Merck’s vaccines weren’t expected to be part of the initial immunization push in the U.S., the development comes amid heightened anxiety over vaccine supplies and a sluggish pace of injections. The emergence of new variants of the coronavirus has also raised questions about whether the shots that have been cleared will lose effectiveness as the pathogen mutates.The failure of Merck’s candidates will also leave it locked out of a market that could eventually be dominated by two of its historic U.S. rivals. Pfizer was the first drugmaker to gain authorization for a Covid vaccine in the U.S., followed closely by Moderna. Johnson & Johnson is expected to publish data in the coming weeks on its vaccine’s efficacy and apply for an emergency-use authorization.Neither of Merck’s candidates was among the six vaccines in the U.S.’s Operation Warp Speed portfolio, though its leadership watched them closely. The drugmaker and its development partner on V590, the International AIDS Vaccine Initiative, did receive some research funding from the government. Its second candidate, V591, relies on technology first developed by France’s Institut Pasteur. Both of the single-dose candidates were well tolerated in early human studies.Kenilworth, New Jersey-based Merck will record a charge for the fourth quarter of 2020 for costs related to halting the programs. It didn’t disclose the amount of the charge Monday. The early-stage trial results will be submitted to a peer-reviewed medical journal.A continuing surge in infections has highlighted the need for more treatment options. Merck will steer resources toward two drugs it has in late-stage development to combat the disease, according to Kartsonis.Read More: Merck-U.S. Deal for Covid Drug Shows Need for Therapies Persist“In the world of pharmaceutical development, a quick kill is not a bad thing because it allows you to reposition and repurpose your assets,” he said.Several of Merck’s vaccine manufacturing facilities are being re-tooled to produce one of its Covid-19 drug candidates, MK-7110, which is complex and difficult to manufacture at mass scale. In an interim study, the intravenous therapy significantly improved the likelihood and speed of recovery for severe and critical Covid-19 patients needing oxygen, reducing the risks of respiratory failure and death by more than 50%. Full study results are expected in the first quarter.Merck’s executives expect U.S. regulators will grant an emergency-use authorization for the drug following those results, and Kartsonis said it could reach sick patients by the middle of the year. The U.S. has already agreed to pay $365 million for 60,000 to 100,000 doses.Antiviral PillMerck is also working on a pill for Covid-19 patients at earlier stages of the disease. Known as molnupiravir, the antiviral therapy was discovered by scientists at Emory University and is being studied in late-stage trials in both hospital and outpatient settings. Merck and partner Ridgeback Biotherapeutics LP expect to have initial data on the drug’s effectiveness in the first quarter, and to wrap up studies in May, the company said in a statement.Chief Marketing Officer Michael Nally said in December that Merck expects a regulatory clearance shortly after the company reports data, should it prove successful.Read More: Single Rolodex Helps Operation Warp Speed Live Up to Its NameThe antiviral is intended to be taken twice a day over five days, for a total of ten capsules. Merck anticipates it will be able to produce more than 20 million courses of the treatment, or 200 million capsules, in 2021, Nally said.The slow vaccine rollout shows that a need for therapeutics will persist, Kartsonis said, and the drugs could work against future viruses.(Updates with Institut Pasteur involvement and safety studies in ninth paragraph. Due to incorrect information provided by the company, a previous version of this article corrected the 10th paragraph to say that Merck’s charge for closing the vaccine program will be after-tax.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Former Blues midfielder leaves the club ninth in the Premier League table, 11 points off top spot after a summer transfer window of massive spending
The "Qatar Midstream Oil and Gas Industry Outlook to 2025" report has been added to ResearchAndMarkets.com's offering.
Kathy Curtis Kathy Curtis Joins Capital Bank Board of Directors ROCKVILLE, Md., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Capital Bank, N.A. Today, Capital Bank is pleased to announce that Kathy Curtis is joining the Capital Bank Board of Directors. Curtis oversaw the development of audit and compliance functions for Capital Bank during a period of extraordinary asset growth and increased regulation. In 2020, Curtis retired from the Bank in her role as Chief Risk/Compliance Officer. Curtis will now rejoin Capital Bank as a member of the Capital Bank Board of Directors. Over her 18 years working with Capital Bank, Curtis was charged with ensuring regulatory compliance and measuring essential operating risks. Her deep expertise in both compliance and risk management, and longstanding relationships with regulators, made her a unique asset to the Bank, as she was both nimble and responsive to an ever-changing banking environment. “Kathy will bring a wealth of knowledge and expertise to the Board. She understands the balance between risk and reward and the importance of a collaborative working relationship with our regulators,” says James F. Whalen, Chairman of the Board of Directors. “We look forward to Kathy’s guidance at the Board level as we execute our growth and fintech initiatives.” ABOUT CAPITAL BANCORP, INC.Capital Bancorp, Inc., Rockville, Maryland is a registered bank holding company incorporated under the laws of Maryland. The Company’s wholly-owned subsidiary, Capital Bank, N.A., is the fifth largest bank headquartered in Maryland at September 30, 2020. Capital Bancorp has been providing financial services since 1999 and now operates bank branches in five locations in the greater Washington, D.C. and Baltimore, Maryland markets. Capital Bancorp had assets of approximately $1.9 billion at September 30, 2020 and its common stock is traded in the NASDAQ Global Market under the symbol “CBNK.” More information can be found at the Company’s website www.CapitalBankMD.com under its investor relations page. FINANCIAL CONTACT: Alan Jackson (240) 283-0402MEDIA CONTACT: Ed Barry (240) 283-1912WEB SITE: www.CapitalBankMD.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8c7aefff-2e73-4d13-9d8a-ac2997c14a8f
during the forecast period. Market growth is driven by factors such as growth in stem cell research, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, rising prevalence of cancer, and growing focus on personalized medicine.New York, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Single-cell Analysis Market by Cell Type, Product, Technique, Application, End User - Forecast to 2025" - https://www.reportlinker.com/p06010123/?utm_source=GNW On the other hand, the high cost of single-cell analysis products is expected to limit market growth to a certain extent in the coming years.The consumbles segment accounted for the highest growth rate in the Asia Pacific single-cell analysis market, by product, during the forecast periodThe Asia Pacific single-cell analysis market is segmented into consumables and instruments based on product.The consumables segment accounted for the highest growth rate in the Asia Pacific single-cell analysis market in 2019.The frequent purchase of consumables as compared to instruments is the main factor contributing to this segment’s high growth rate.Next-generation sequencing segment accounted for the highest CAGRBased on technique, the APAC single-cell analysis market is segmented into flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques.In 2019, the next-generation sequencing segment accounted for the highest growth rate.The advancements in NGS techniques and their wide application in drug discovery for cancer are the major factors driving this segment’s growth.Academic & research laboratories segment accounted for the highest CAGRBased on end user, the APAC single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers.In 2019, the academic & research laboratories segment accounted for the highest growth rate.This can be attributed to the increasing number of collaborations among research institutes and life science research companies and growing funding for life science research.Japan: The fastest-growing country in the Asia Pacific single-cell analysis marketThe Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific.Japan is projected to register the highest CAGR during the forecast period.Factors such as the increasing life science research activities, increasing demand for advanced treatment techniques, and growing focus on personalized medicine are driving the growth of the single-cell analysis market in Japan.The primary interviews conducted for this report can be categorized as follows:• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%• By Designation: C-level - 27%, D-level - 18%, and Others - 55%Lists of Companies Profiled in the Report:• Becton, Dickinson and Company (US)• Danaher Corporation (US)• Merck Millipore (US)• QIAGEN N.V. (Netherlands)• Thermo Fisher Scientific, Inc. (US)• General Electric Company (US)• Promega Corporation (US)• Illumina, Inc. (US)• Bio-Rad Laboratories (US)• Fluidigm Corporation (US)• Agilent Technologies, Inc. (US)• Tecan Group Ltd. (Switzerland)• Sartorius AG (Germany)• Luminex Corporation (US)• Takara Bio (Japan)• 10x Genomics (US)• Fluxion Biosciences (US)• Menarini Silicon Biosystems, Inc. (Italy)• bioMérieux SA (France)• Oxford Nanopore Technologies (UK)• Cytek Biosciences (US)• Corning Incorporated (US)• Apogee Flow Systems Ltd. (UK)• NanoCellect Biomedical (US)• On-chip Biotechnologies Co., Ltd. (Japan)Research Coverage:This report provides a detailed picture of the Asia Pacific single-cell analysis market.It aims at estimating the size and future growth potential of the market across different segments, such as product, cell type, technique, application, end user, and country.The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific single-cell analysis market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.Read the full report: https://www.reportlinker.com/p06010123/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
French prosecutors demanded long prison sentences on Monday for an Italian restaurant manager and a hard-up British ex-soldier who are accused of kidnapping an ageing hotel heiress in the city of Nice.
(Bloomberg) -- AMC Entertainment Holdings Inc. said it was no longer at risk of an imminent bankruptcy filing after assembling $917 million of fresh financing, continuing its fight to fend off the effects of Covid-19 on its theater business.The world’s largest cinema chain’s shares soared as much as 50% in premarket trading and were up 35% to $4.75 at 8:41 a.m. in New York. And AMC’s bonds were among the biggest gainers in the U.S. high-yield market on Monday. The second-lien notes rose as much as 12.75 cents on the dollar to a high of 52.25 cents, according to Trace bond trading data.The Leawood, Kansas-based company has raised $506 million of equity, after securing $100 million of additional first-lien debt and converting $100 million of second-lien debt into equity, it said in a statement Monday. It also said it executed commitment letters for $411 million of new debt through mid-2023.“Any talk of an imminent bankruptcy for AMC is completely off the table,” AMC Chief Executive Officer Adam Aron said.AMC’s deal already has backing from a combination of debt and equity issued in recent months, according to the statement. With the new money, AMC says it extended its financial runway “deep” into 2021, a timeline in which theater chains are waiting for coronavirus vaccines to be widely distributed and moviegoers to return for blockbuster releases.AMC estimated it could hold out through July in the absence of any increase in attendance, and assuming continued concessions from landlords, who were owed $450 million as of Dec. 31, according to a regulatory filing. AMC said it has stopped rent payments on “a substantial portion” of its leases and that it’s received default notices.“Looking ahead, for AMC to succeed over the medium term, we are going to need for much of the general public in the U.S. and abroad to be vaccinated,” Aron said in the statement.The company cautioned that even with a vaccine and increase in cinema attendance, the virus could worsen or other strains could appear, causing its use of cash to remain uncertain. Accordingly, AMC said it’s looking at potential additional sources of liquidity it may pursue in the future.Landlord TalksAMC said at the end of last year that it needed to raise at least $750 million to stay in business. Without new money, its existing cash would have been depleted as soon as this month. The company has also been talking with its landlords to amend terms of certain leases and avoid a potential cash crunch.The latest financing deal includes a loan of 400 million pounds ($547 million) to its U.K. subsidiary Odeon Cinemas Group Ltd., which will refinance a 100 million-pound revolving facility and provides 300 million pounds of liquidity. The transaction is subject to the consent of Silver Lake Management, majority holder of AMC’s convertible notes due 2026.The $100 million in first-lien debt proceeds came from a sale of payment-in-kind notes due 2026 to Mudrick Capital Management on Jan. 15, AMC said.Theater chains have been hard hit by government-mandated shutdowns during the Covid-19 pandemic. While some locations have been able to reopen at limited capacity, many moviegoers have been reluctant to attend. The problem has been compounded by studios delaying major releases that drive ticket sales.In the filing Monday, AMC said fourth-quarter attendance fell about 92% in the U.S. and 89% internationally from the same period a year ago, and it was burning cash at about $124 million a month.(Updates with bonds in second paragraph, additional details from fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.